Cargando…
Benefit versus toxicity risk of digoxin in patients with COVID-19
Autores principales: | Kelleci Cakir, Burcu, Bayraktar-Ekincioglu, Aygin, Demirkan, Kutay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614171/ https://www.ncbi.nlm.nih.gov/pubmed/34083222 http://dx.doi.org/10.1136/ejhpharm-2021-002880 |
Ejemplares similares
-
Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?
por: Yalçın, Nadir, et al.
Publicado: (2021) -
Treatment of life-threatening digoxin toxicity with digoxin-specific antibody fragments: results from a prospective, non-interventional observational UK patient registry study
por: Thomas, Emma, et al.
Publicado: (2023) -
Methanol toxicity outbreak: when fear of COVID-19 goes viral
por: Sefidbakht, Sepideh, et al.
Publicado: (2020) -
Is sitagliptin effective for the treatment of COVID-19?
por: Memiş, Hasan, et al.
Publicado: (2022) -
Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation
por: Zhan, Ke, et al.
Publicado: (2021)